Cognitio

In this episode of the Cognitio Podcast, host Tim Boyle explores one of the most critical equity challenges in Australian healthcare: ensuring safe, effective, culturally informed use of medicines for First Nations peoples.

Tim is joined by four respected leaders in medicine safety: Karen Battat (AstraZeneca), Vinham Mehta (Novartis), Marcela Bade (former TGA pharmacovigilance inspector) and Matt Iglesias, who together unpack the unique risk factors, data gaps and cultural considerations that influence pharmacovigilance in First Nations communities.

The conversation highlights why First Nations representation in safety data remains low, the impact this has on signal detection and patient outcomes, and what meaningful, practical steps the sector can take — from culturally grounded educational materials to strengthened community partnerships and more robust system design.

This episode is essential listening for anyone working in regulatory affairs, pharmacovigilance, clinical operations, public health or industry leadership. It’s a powerful reminder that medicine safety is not just a technical obligation, but a commitment to fairness, respect and culturally responsive practice.

Join the ARCS community as a Professional Member — or bring your whole organisation on board — to stay connected, informed and engaged with the conversations shaping the future of the life sciences sector.

This week’s wrap brings you the biggest developments across Australia’s life sciences sector — all in one quick, engaging update. We cover major pharma moves, medtech breakthroughs, biotech investment momentum, regulatory updates, and the latest people movements shaping the industry.

From gene therapy and GLP-1 dealmaking to AI in radiology and standout Australian clinical results, this episode highlights the trends influencing policy, access, capability and commercialisation right now.

If you want to stay informed, connected and ahead of sector shifts, this is the update you don’t want to miss.

Watch now and get the week’s essential insights — fast.

What is Intellectual Property? A Practical Guide for Australia’s Life Sciences Sector

In this episode of Cognitio, Tim Boyle takes listeners on a clear and engaging tour of the intellectual property landscape, guided by three specialists from Spruson and Ferguson Lawyers. IP sits at the core of innovation and commercialisation in the life sciences, yet it is often misunderstood or overlooked until problems arise. This conversation breaks it down in a way that is accessible, practical, and directly relevant to researchers, clinicians, entrepreneurs, and anyone navigating discovery-to-market pathways.

Dr Katherine Winbanks opens with an IP 101 masterclass, covering patents, trade marks, copyright, confidential information, and the risks of early disclosure. Sylvie Tso then steps through the commercialisation process, unpacking licensing, assignments, royalties, valuation challenges, and how to structure deals that actually create value. Finally, Katrina Crooks explains what happens when IP is infringed and how disputes are managed, from demand letters to litigation, injunctions, and enforcement of rights.

Across the episode, the message is clear: strong IP strategy is essential for protecting innovation, attracting investment, and strengthening Australia’s position as a global life sciences leader.

If you work in research, biotech, medtech, clinical trials, or commercialisation, this is an episode you won’t want to miss.

In this week’s episode, Anna Megalakakis steps behind the mic to bring you a fast-paced and insightful roundup of the biggest developments across Australia’s life sciences sector. From blockbuster pharma shifts and cutting-edge medtech launches to biotech investment momentum and major leadership movements, this episode unpacks what matters — and why.

Anna also shares the latest from ARCS, including highlights from the HBA Sydney anniversary event, updates on the National Clinical Trials Governance Framework consultations, and fresh opportunities to get involved in the 2026 ARCS Annual Conference and the newly expanded 2025 Clinical Summit. Plus, hear about ARCS’ brand-new Enterprise Partnership model, offering organisations a powerful way to invest in their people.

In this episode:

• Pharma: Tirzepatide’s global rise, PBS expansions, and shifting clinical trial landscapes.

• Medtech: AI-powered imaging tech, next-gen valves, and long-term innovation partnerships.

• Biotech & Investment: Capital milestones, regulatory progress, and clinical breakthroughs.

• People Movement: Key promotions, awards, and leadership shifts across the sector.

• Partner With ARCS: How enterprise memberships can elevate your workforce and brand.

Whether you work in clinical trials, regulatory affairs, medical affairs, biotech, medtech, policy, or beyond — this episode gives you the insights you need to stay ahead.

Listen now and stay connected to the news shaping Australia’s life sciences future. And if you haven’t already — now’s the perfect time to join ARCS Australia and be part of the country’s largest professional community in our sector.

In this episode of The Cognitio Podcast, ARCS Australia CEO Tim Boyle introduces highlights from a thought-provoking ARCS Interest Area webinar, Automating Life Science Workflows through AI, presented by Dr Rishi Verma, CEO and Founder of Stethy AI.

Dr Verma, a physician and engineer, takes listeners inside the fast-evolving world of artificial intelligence in the life sciences. Drawing directly from his presentation, he explains — in his own words — how AI is transforming the daily realities of regulatory affairs and pharmacovigilance, from document authoring and quality control to horizon scanning and compliance monitoring.

Through real-world examples, including a compelling case study from Roche, Dr Verma demonstrates how AI can reduce manual workloads, improve accuracy, and accelerate submissions — while keeping human expertise firmly at the centre of every decision.

This episode is a must-listen for regulatory professionals, clinical researchers, and anyone navigating the intersection of technology, compliance, and patient safety.

🎧 Tune in to learn how AI is reshaping the way we work — not by replacing professionals, but by empowering them to focus on strategy, quality, and innovation.

This week’s episode dives into the biggest stories shaping Australia’s life sciences landscape — from global leadership milestones to biotech breakthroughs and policy reform.

We celebrate Professor Tony Lawler’s appointment as Global Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA), marking Australia’s growing influence in global regulatory science.
In pharma, Takeda, Pfizer, and Boehringer Ingelheim make bold moves, while new funding under the Life Saving Drugs Program delivers long-awaited hope for rare disease patients.

The biotech sector surges ahead with the opening of Australia’s first Viral Vector Manufacturing Facility in Westmead and major international deals, including Novartis’s $18.4B acquisition of Avidity Biosciences.
Meanwhile, medtech innovation keeps pace as CSL Seqirus expands its global vaccine partnerships and Medicare boosts access to diagnostics.

Plus, we spotlight leadership shifts at AbbVie, Uniseed, and PolyNovo, and Nav Lee’s representation of ARCS on the world stage in Cairo.

🎧 Tune in for insights, context, and commentary on how these developments are shaping Australia’s clinical trials, biotech, and medtech future.

Next Generation Nuclear Medicine: Powering the Future of Precision Health

In this episode of ARCS Cognitio, ARCS Australia CEO Tim Boyle leads a compelling conversation on the rapidly evolving world of next-generation nuclear medicines — where physics meets biology to transform how we diagnose and treat disease.

Joined by a panel of industry leaders — Christian Behrenbruch (Telix Pharmaceuticals), David James (formerly Sirtex Medical and OncoSil), Rosanne Robinson (Clarity Pharmaceuticals, ex ANSTO, and Cylotek), and Brad Walsh (Glytherix) — the discussion explores the technologies, supply chain challenges, and investment opportunities shaping the future of this dynamic sector.

From emerging isotopes and theranostics to Australia’s unique position as a regional hub for radiopharmaceutical innovation, this episode offers deep insights into one of the most exciting frontiers in modern medicine.

Tune in to discover how collaboration, capability, and clinical excellence are driving the next era of nuclear medicine — and how Australia can lead the charge.

🎧 Listen now and join the conversation at arcs.com.au.

ARCS Weekly News Wrap – Week Ending 25 October 2025

This week’s episode covers a powerhouse mix of policy shifts, scientific breakthroughs, and leadership changes shaping Australia’s life sciences landscape.

Join Tim Boyle, CEO of ARCS Australia, as he unpacks:

• Pharma: Landmark PBS listings, proactive pharmacovigilance, and new rare disease breakthroughs

• Medtech: HTA review tensions, hospital funding reform, and insights from the MTAA Conference

• Biotech & Investment: A wave of clinical trials, capital raises, and global research collaborations

• People Movement: Leadership transitions at Gilead, Moderna, and Omico that will influence the sector’s next chapter

• Partner with ARCS: How collaboration continues to drive innovation and workforce capability across the life sciences ecosystem

It’s a fast-paced, insightful wrap of the week’s most important developments — helping you stay informed, connected, and ahead of the curve.

🎥 Watch the full episode now and don’t miss your chance to be part of the only professional network that connects every corner of the Australian life sciences sector.

👉 Join ARCS today: www.arcs.com.au/join

#ARCSWeeklyWrap #LifeSciences #Pharma #Medtech #Biotech #ARCSAustralia #ARCS2025Leaders

In this week’s ARCS Weekly News Wrap, Tim Boyle returns from Adelaide after the KCA Conference to bring you the top stories shaping Australia’s life sciences sector.

This episode covers:
• Pharma: FDA approval for MSD’s subcutaneous Keytruda, Eli Lilly’s oral obesity drug heading to the TGA, and J&J’s Stelara patent challenge.
• Medtech: AI-assisted diagnostics at Macquarie University and Optain Health’s new Melbourne research hub.
• Biotech and Investment: Momentum from Clarity Pharmaceuticals, Telix, and Chimeric Therapeutics as local innovation continues to accelerate.
• People Movement: Leadership changes across Novartis, Boehringer Ingelheim, and Boston Scientific.

Tim also reminds listeners that early bird pricing for the ARCS Clinical Summit closes 20 October and that places are still available for the upcoming Pharmacovigilance Inspections course.

Stay informed, stay connected, and join the conversation with ARCS Australia – the professional home for Australia’s medtech and pharmaceutical sector.

#ARCSAus #Pharma #Medtech #Biotech #LifeSciences #ClinicalResearch #ARCSWeeklyNewsWrap

This week’s ARCS Weekly News Wrap dives into the biggest stories shaping pharma, medtech, biotech, and the workforce behind them. From the MAPA-MAPS Summit and student careers fairs to global debates over paracetamol, robotic surgery innovations, and major biotech funding deals — we break it all down and explain what it means for you.

Highlights include:

• The rise of medical affairs and ARCS’ careers outreach

• Pharma headlines from Trump to the TGA

• Cutting-edge medtech adoption and diagnostic breakthroughs

• Next-gen biotech therapies and major investment wins

• Sanofi’s HQ move, workforce pay trends, and hot skills in demand

• New ventures and global collaborations driving patient-centred innovation

Stay informed, stay connected, and join ARCS to be part of the professional community leading Australia’s medtech, pharma, and biotech sectors forward.